Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com
Vir Biotechnology Inc. (NASDAQ:VIR) will present Phase 2 SOLSTICE trial data for its hepatitis delta treatments, tobevibart and elebsiran, at the EASL Congress 2026 in Barcelona. The presentation will cover Week 96 efficacy and safety results for combination therapy, with a separate poster on the impact of BMI on ALT normalization. Despite significant stock returns, InvestingPro analysis suggests the stock is currently overvalued, and the company recently reported a substantial miss on Q1 2026 earnings expectations.
Vir Biotechnology to present hepatitis delta trial data at EASL
Vir Biotechnology (NASDAQ:VIR) is set to present Phase 2 SOLSTICE trial data for its chronic hepatitis delta treatments, tobevibart and elebsiran, at the EASL Congress 2026. The presentation will cover Week 96 endpoint results and Week 48 subgroup data, highlighting the efficacy and safety of the treatments. Despite a 91% return over the past year, the company recently reported a significant Q1 2026 earnings and revenue shortfall, and its stock is considered overvalued according to InvestingPro.
New hepatitis delta drug combo data lands ‘Best of EASL 2026’ slot
Vir Biotechnology announced it will present complete Week 96 data from its Phase 2 SOLSTICE trial for chronic hepatitis delta at the EASL Congress 2026. The key oral presentation, showing results for tobevibart and elebsiran, was selected for inclusion in "Best of EASL 2026," while a poster presentation will detail subgroup analysis on how BMI impacts ALT normalization. This combination therapy aims to disrupt the hepatitis delta virus life cycle at multiple points.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
SB Investment Advisers (UK) Ltd significantly reduced its stake in Vir Biotechnology by selling over 2.1 million shares worth an estimated $17.28 million, despite the stock nearly doubling in the past year. This move is seen as portfolio management rather than a complete withdrawal, as Vir Biotechnology remains a notable holding for SB Investment Advisers. The company is focusing on evolving beyond its pandemic-era identity, with advancements in its oncology and hepatitis delta programs.
Boxer Capital Management Boosts Vir Biotechnology Holdings in Q1 2026 Filing - News and Statistics
Boxer Capital Management increased its stake in Vir Biotechnology (NASDAQ:VIR) by purchasing 1,241,000 additional shares worth $9.89 million in Q1 2026. This acquisition raised Vir Biotechnology's representation to 2.2% of Boxer Capital Management's 13F reportable assets under management. Vir Biotechnology's shares have risen approximately 100% over the past year, outperforming the S&P 500, despite the company reporting negative net income.
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR)
A SoftBank-affiliated group, including SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M1) L.P., and SVF Endurance (Cayman) Limited, has disclosed a shared beneficial ownership of 10,948,093 shares (6.5%) in Vir Biotechnology (VIR). This stake was reported as of March 31, 2026, with 168,651,974 shares outstanding as of April 29, 2026. The filing indicates shared voting and dispositive power among the reporting entities, with SBIA UK acting as the alternative investment fund manager (AIFM).
Vir Biotechnology, Inc. - Common Stock (Nasdaq:VIR) Stock Quote
This page provides a detailed stock quote for Vir Biotechnology, Inc. (Nasdaq:VIR), including current trading data, recent performance metrics, and a compilation of news headlines related to the company. Key financial information like trading volume, price ranges, shares outstanding, and market capitalization are also presented. The news section highlights recent events such as earnings calls, analyst reports, corporate updates, and insider stock transactions.
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR
Vanguard Group Inc. decreased its holding in Vir Biotechnology, Inc. by 2.0% in the fourth quarter but remains the largest disclosed shareholder with 12.55 million shares. Despite a weak latest quarter with a significant EPS loss and revenue miss, analysts maintain a "Moderate Buy" consensus rating with a target price of $20.25. Insider selling activity also occurred recently, with the stock trading around $9.09.
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips
Vir Biotechnology (VIR) reported significantly wider losses and a substantial revenue miss for Q1 2026, with an EPS of -$0.85 against a forecast of -$0.10 and negative revenue. Following the announcement, the stock dropped 7.39% in after-hours trading. Despite the financial setback, the company maintains a strong cash position, bolstered by a recent collaboration with Astellas, and is advancing its oncology and hepatitis delta programs with several upcoming clinical milestones.
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips
Vir Biotechnology (VIR) reported significant misses for its Q1 2026 earnings, with an EPS of -$0.85 against a forecasted -$0.10, and negative revenue of -$29,000 versus a projected $55.89 million. This led to a 7.39% drop in its stock price during after-hours trading. Despite wider net losses, the company highlighted a strong cash position extending into late 2028 due to a collaboration with Astellas and a recent equity offering, and discussed the progress across its oncology and hepatitis delta programs.
Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright
HC Wainwright has reduced its Q2 2026 EPS estimate for Vir Biotechnology to $0.56 from $0.73, while maintaining a "Buy" rating and a $20 price target. This revision comes after Vir Biotechnology reported a larger-than-expected quarterly loss and lower revenue, leading to adjusted forecasts for continued losses and slower profitability through 2030. Other analysts have offered mixed ratings, with an average "Moderate Buy" rating and a $20.25 target price for the company.
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Vir Biotechnology, Inc. (NASDAQ:VIR) reported a surprise loss in its first-quarter earnings, with revenues falling short by 100% and a loss of US$0.85 per share against analyst expectations of a profit. Despite this, analysts have modestly increased revenue forecasts for 2026 to US$249.4m (a 281% improvement), though per-share loss expectations have also slightly increased to US$1.45. The consensus price target remains unchanged at US$20.56, indicating that the predicted significant revenue growth is seen as enough to offset the increased loss forecasts.
Vir Biotechnology (NASDAQ:VIR) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Vir Biotechnology (NASDAQ:VIR) to a "sell" rating from a "hold," citing a much weaker-than-expected financial quarter where the company missed EPS and revenue estimates significantly. Despite this, the company still holds a "Moderate Buy" consensus rating from analysts with a target price of $20.25. Insider selling has also been noted, with executives and directors selling shares recently, though institutional investors still hold a majority stake.
VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Vir Biotechnology (VIR) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It aggregates these official regulatory documents and enhances them with AI-generated summaries, impact scoring, and sentiment analysis to help investors and traders understand key points. The most recent filing, dated July 24, 2025, disclosed the initiation of a first-in-human study for VIR-5525, expanding the company's oncology pipeline.
Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028
Vir Biotechnology expects to initiate a Phase III study for its HIV asset, VIR-5500, in 2027. The company's financial projections indicate a cash runway extending into the second half of 2028. This outlook balances clinical development timelines with fiscal sustainability for future operations.
Vir Biotechnology (Nasdaq: VIR) extends cash runway into 2H 2028
Vir Biotechnology reported a net loss of $125.7 million for Q1 2026 and ended the quarter with $809.3 million in cash, cash equivalents, and investments. The company, which recently completed an equity offering and expects additional proceeds from an Astellas collaboration, has extended its cash runway into the second half of 2028. Vir also provided updates on its chronic hepatitis delta and oncology pipeline programs, including positive Phase 2 SOLSTICE data and progress in its ECLIPSE registrational program.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology announced its first-quarter 2026 financial results, highlighting significant progress in its clinical pipeline. Key achievements include the closing of a global collaboration with Astellas for the prostate cancer treatment VIR-5500, with the first patient dosed in Phase 1 dose-expansion cohorts, and the anticipation of presenting complete Week 96 Phase 2 SOLSTICE data for its chronic hepatitis delta (CHD) combination regimen. The company also reported a strong financial position with $809.3 million in cash and investments and expects its current funds to last into the second half of 2028.
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology announced its first-quarter 2026 financial results, reporting a strong cash position of $809.3 million and outlining significant progress in its clinical programs. Key updates include the closing of a global collaboration with Astellas for the PSMA-targeted T-cell engager VIR-5500, with the first patient dosed in Phase 1 dose-expansion cohorts, and upcoming presentation of complete Week 96 Phase 2 SOLSTICE data for its chronic hepatitis delta (CHD) combination regimen. The company also detailed expectations for Phase 3 CHD trial data and financial guidance forecasting operations funding into the second half of 2028.
Astellas collaboration brings $315M to Vir Biotechnology (VIR)
Vir Biotechnology reported a Q1 2026 net loss of $125.7 million, with minimal revenue, largely due to heavy investment in its hepatitis delta and oncology programs. The company maintained a strong cash position of $809.3 million, bolstered by a February equity offering. Subsequent to the quarter-end, Vir closed a significant collaboration with Astellas for its prostate cancer candidate VIR-5500, securing $315 million in upfront payments and equity investment.
Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results
Vir Biotechnology (NASDAQ:VIR) reported a significant earnings miss for the quarter, with an adjusted EPS of ($0.85) against a consensus of ($0.01) and revenue of ($0.03) million versus an expected $55.49 million. Despite insider selling activity, analyst sentiment remains generally positive, with a "Moderate Buy" consensus and an average price target of $20.38, reflecting potential upside. The company's stock, VIR, traded up $0.28 on Wednesday to $10.29, and institutional investors have been adjusting their positions.
Vir Biotechnology (Nasdaq:VIR) - Stock Analysis
Vir Biotechnology, Inc. (Nasdaq:VIR) is a clinical-stage biopharmaceutical company focused on infectious diseases, with a market cap of US$1.7 billion. The stock is currently deemed 55.4% undervalued by analysts, with revenue forecast to grow 17.8% annually, but the company is unprofitable and has experienced shareholder dilution. Recent news highlights a collaboration with Astellas for VIR-5500 in prostate cancer and encouraging Phase 2 data for chronic hepatitis delta, alongside disappointing Q1 2026 earnings.
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 75c, offers outlook
Vir Biotechnology Inc. (VIR) reported a Q1 EPS of ($0.85), missing analyst estimates by $0.75, and recorded $0 in revenue against an estimated $55.89 million. Despite the financial miss for the quarter, the company provided a positive financial outlook, expecting its cash, cash equivalents, and investments to fund operations into the second half of 2028. This guidance includes the effects of the Astellas global collaboration, equity investment, and a recent equity financing.
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss
Vir Biotechnology (VIR) reported a larger-than-expected Q1 2026 loss of $0.85 per share against a forecast of -$0.10, resulting in a 750% EPS surprise. Despite the significant miss, the stock saw a 1.4% increase in aftermarket trading, bolstered by a strong cash position of $809.3 million and a strategic collaboration with Astellas valued at up to $1.7 billion for their VIR-5500 prostate cancer program. The company also highlighted promising results from its hepatitis delta program, with a monthly combination therapy showing potential best-in-class efficacy and convenience.
Vir Biotech investors brace for earnings as losses shrink By Investing.com
Vir Biotechnology Inc. is anticipated to report sharply narrowed losses for its first-quarter earnings, driven by progress in its chronic hepatitis delta therapy. Analysts project a loss of 10 cents per share on revenue of $55.89 million, with all 10 analysts rating the stock a "Strong Buy" and significant upside potential. Investors will be closely watching the company's path to profitability, revenue composition, and pipeline advancements beyond hepatitis delta.
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology, Inc. announced that CEO Marianne De Backer will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12. A live webcast of the event will be available on the company's investor relations website. The company is a clinical-stage biopharmaceutical firm focusing on infectious diseases and cancer.
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology, Inc. announced that CEO Marianne De Backer will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast and archive of the event will be available on the company's investor relations website. The company is a clinical-stage biopharmaceutical firm focused on developing medicines for serious infectious diseases and cancer.
Vir Biotechnology Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for Vir Biotechnology. It is awaiting content to offer further details on expectations or financial forecasts.
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology announced that its CEO, Marianne De Backer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12. The event will be held in Las Vegas and a live webcast will be available on the company's investor relations website. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.
Vir Biotechnology director Vicki Sato sells $221,025 in stock
Vicki L. Sato, a director at Vir Biotechnology, Inc. (NASDAQ:VIR), sold 22,000 shares of the company's common stock for approximately $221,025. This sale was made under a Rule 10b5-1 trading plan and follows a 62% surge in VIR shares over the past year, with the stock currently trading above its InvestingPro Fair Value. The article also mentions recent positive developments for Vir Biotechnology, including a collaboration with Astellas Pharma and a successful public offering.
Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of the company’s common stock for approximately $221,025 on May 1, 2026, under a Rule 10b5-1 trading plan. This insider sale follows a 62% surge in VIR shares over the past year, with the stock currently trading above its InvestingPro Fair Value. The company has also been active with a new collaboration agreement for a prostate cancer treatment, a successful public offering raising $172.5 million, and increased price targets from analysts.
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares
Vir Biotechnology Director Vicki Sato sold 22,000 shares of the company's stock for $221,100, reducing her stake by 2%. The sale was part of a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly results with significant year-over-year revenue growth and holds a "Moderate Buy" consensus rating from analysts.
Vir Biotechnology (VIR) director sells 22,000 shares under 10b5-1 plan
Vir Biotechnology Inc. director Vicki L. Sato sold 22,000 shares of common stock on May 1, 2026, at an average price of $10.0466 per share, totaling approximately $221,025. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025. Following the sale, Sato still directly owns 1,078,391 shares of the company, indicating the sale represents a small portion of her total holdings.
Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com
Vicki L. Sato, a director at Vir Biotechnology, Inc. (NASDAQ:VIR), sold 22,000 shares of the company’s common stock for approximately $221,025. This sale was conducted under a Rule 10b5-1 trading plan adopted in March 2025 and follows a 62% surge in VIR shares over the past year. The company has also recently completed a collaboration with Astellas Pharma for a prostate cancer treatment, dosed the first patient in an expansion cohort for a Phase 1 trial of VIR-5500, and raised $172.5 million in a public offering.
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR) has received an average "Moderate Buy" rating from nine analysts, with a consensus one-year price target of $20.38. Despite recent insider selling totaling $2.33 million and a deeply negative net margin, the company beat its last quarterly earnings estimates for both EPS and revenue, with revenue soaring 417.8% year-over-year. Institutional investors have also been adjusting their positions in the stock.
Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust
Vir Biotechnology's President & CEO, Marianne De Backer, has restructured her common stock holdings, reclassifying a total of 467,064 shares into a family trust for tax and estate planning. This transaction, reported via Form 4, involves two entries of 233,532 shares each, shifting ownership without consideration rather than a market buy or sell. Following the changes, she holds 714,613 direct shares and 286,650 indirect shares through the Ureel-De Backer Family Trust.
[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%)
Vanguard Portfolio Management has disclosed a passive investment in Vir Biotechnology Inc., reporting beneficial ownership of 9,257,235 shares, which represents 5.79% of the company's common stock. This Schedule 13G filing indicates a large passive stake by Vanguard, consistent with typical index or managed-fund holdings, and does not suggest activist intent. The filing details Vanguard's sole dispositive power over all shares and sole voting power over a limited number of shares, as managed by its affiliated business divisions and funds.
Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday
Vir Biotechnology (NASDAQ:VIR) is expected to release its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts forecasting a loss of ($0.01) per share and revenue of $55.4890 million. The company reported better-than-expected results in its previous quarter, with revenue up 417.8% year-over-year. Wall Street analysts generally have a "Moderate Buy" rating for VIR, with an average target price of $20.38, though insider selling has also been noted.
Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
Needham has reiterated its Buy rating on Vir Biotechnology (VIR.US) and maintained its target price at $18. This indicates the firm's continued confidence in the company's prospects.
Certain Common Stock of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026.
This article announces that certain common stock of Vir Biotechnology, Inc. are subject to a lock-up agreement ending on April 27, 2026. The lock-up period began on February 25, 2026, and prevents the company, its directors, and executive officers from disposing of these shares without prior consent from Goldman Sachs & Co. LLC and Leerink Partners LLC. This agreement covers shares for 61 days post-prospectus supplement.
Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026.
Certain stock options of Vir Biotechnology, Inc. are locked up for 61 days, starting from February 25, 2026, and ending on April 27, 2026. This lock-up agreement, covering common stock and convertible securities, was made with underwriters Goldman Sachs & Co. LLC and Leerink Partners LLC. The agreement restricts company directors and executive officers from disposing of or hedging these securities without prior written consent.
Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology will host a conference call to discuss its first-quarter 2026 financial results. The company invites interested parties to join the call at the specified date and time to review its financial performance for the period. Further details regarding access to the conference call will be provided.
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The call details will be available on the Events & Presentations page of the company's website. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases and cancer.
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT. The call will provide a corporate update and discuss financial results for the first quarter ended March 31, 2026. Interested parties can access the call via the Events & Presentations page on the company's website.
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will host a conference call on Wednesday, May 6, at 4:30 p.m. ET (1:30 p.m. PT) to discuss its financial results for the first quarter ended March 31, 2026. The call will also provide a corporate update and can be accessed via the Events & Presentations page on the company's website.
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth
Vir Biotechnology, Inc. (NASDAQ: VIR) has experienced significant growth, with its stock price increasing by 91.62% year-over-year and 80.98% year-to-date. The company recently closed a global collaboration and licensing agreement with Astellas for the development of VIR-5500 for metastatic prostate cancer, receiving an upfront payment of $240 million and an equity investment, with potential for further milestone payments and royalties. Vir Biotechnology specializes in developing medicines for serious infectious diseases and cancer, with a focus on powering the immune system.
Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows
Vir Biotechnology announced the closing of its collaboration and licensing agreement with Astellas, securing an upfront payment of US$240 million, a US$75 million equity investment, and potential milestone payments. This deal significantly boosts Vir's cash position and shares U.S. profit-and-loss specifics for its metastatic prostate cancer drug candidate, VIR-5500, which is currently in Phase 1 trials. The partnership validates the VIR-5500 program and strengthens Vir's funding, while the company continues to manage clinical and execution risks across its broader pipeline.
Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial
Vir Biotechnology, Inc. has begun dosing patients in new expansion cohorts for its Phase 1 clinical trial of VIR-5500, a T-cell engager for metastatic prostate cancer. The company is evaluating VIR-5500 as a standalone therapy and in combination with other inhibitors, targeting the prostate-specific membrane antigen. This development marks a significant step for Vir Biotechnology as it expands its focus on applying immunologic insights to oncology, alongside its existing work in infectious diseases.
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?
Vir Biotechnology (NASDAQ: VIR) has dosed the first patient in an expansion cohort for its Phase 1 trial of VIR-5500, a treatment for metastatic prostate cancer. This investigational drug uses masked T-cell engager technology to target cancer cells expressing PSMA, aiming to reduce risks associated with immune overreaction. The company believes VIR-5500, currently the only dual-masked PSMA-targeting TCE in clinical evaluation, could be a breakthrough for the hardest-to-treat prostate cancer patients.
Vir Biotechnology stock hits 52-week high at $10.94
Vir Biotechnology Inc. has seen its stock price reach a 52-week high of $10.94, driven by a 95% return over the past year and a 78% year-to-date gain, bringing its market cap to $1.7 billion. The company has also completed a collaboration with Astellas Pharma for a prostate cancer treatment and successfully closed a public offering, raising $172.5 million. Analysts from H.C. Wainwright and Leerink Partners have raised their price targets for Vir Biotechnology to $20, maintaining Buy and Outperform ratings, respectively.
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?
Vir Biotechnology, Inc. (NASDAQ: VIR) is highlighted as one of the best low-priced biotech stocks to consider for investment. The company recently announced the dosing of the first patient in a Phase 1 trial for VIR-5500, a T-cell engager targeting metastatic prostate cancer, demonstrating progress in its clinical programs. While recognizing the potential of VIR, the article also pivots to advocating for a specific AI stock with high upside potential, suggesting it might offer greater returns in a shorter timeframe.
